Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah report beneficial ownership of 935,486 shares of Adicet Bio, Inc. common stock as of June 30, 2026, subject to a 9.99% beneficial ownership limitation.
The Fund directly holds 932,624 shares and Pre-Funded Warrants exercisable for up to 1,402,833 shares, but a Beneficial Ownership Blocker in the warrants prevents exercises that would raise aggregate ownership above 9.99% of Adicet’s outstanding common stock. Based on 9,361,371 shares outstanding and 2,862 warrant shares counted for this calculation, each Reporting Person’s beneficial ownership is 9.99% of the class, rounded down to 9.9% in the cover pages due to EDGAR field limits.
RA Capital acts as investment adviser to the Fund and has delegated voting and dispositive power over the Fund’s holdings. The Reporting Persons state that they may be deemed beneficial owners for Section 13(d) purposes but expressly disclaim beneficial ownership except to determine their reporting obligations.
Adicet Bio, Inc. reported that its Chief Medical Officer, Klickstein Lloyd, received a grant of stock options covering 18,300 shares of common stock at an exercise price of $9.16 per share. According to the award terms, 1/6th of the options vest on each of the next six monthly anniversaries of August 5, 2026, subject to continued service, and the options expire on August 4, 2036.
Adicet Bio develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Lead candidate prula-cel, a CD20-targeting CAR gamma delta T cell, is in Phase 1 across multiple autoimmune indications, including lupus nephritis and systemic lupus erythematosus, and has FDA Fast Track designations in several settings. The company is preparing a potential pivotal lupus nephritis/SLE trial for the second half of 2026, subject to regulatory clearance, and advancing ADI-212, a PSMA-targeted candidate for metastatic castration-resistant prostate cancer, toward an initial regulatory submission in the third quarter of 2026.
For the quarter ended June 30, 2026, Adicet reported a net loss of $21.4 million, improved from $31.2 million a year earlier, as research and development expense fell to $18.5 million from $28.4 million while general and administrative costs were stable. The six‑month net loss was $41.6 million, with $41.3 million of net cash used in operating activities. Cash and cash equivalents were $33.1 million, short‑term treasury investments were $85.1 million, and restricted cash was $2.9 million as of June 30, 2026. Management states that this liquidity should fund forecasted operating and capital needs for at least 12 months, but the company remains pre‑revenue and expects to rely on future financings and collaborations.
Adicet Bio, Inc. reported second-quarter 2026 results and outlined upcoming milestones for its gamma delta T cell therapy pipeline. For the quarter ended June 30, 2026, research and development expenses were $18.5 million, general and administrative expenses were $3.9 million, and net loss was $21.4 million, or $1.99 per basic and diluted share. Cash, cash equivalents and short-term investments totaled $118.2 million as of June 30, 2026, which the company expects will fund operations into the second half of 2027.
The company plans a Phase 1 clinical update in the third quarter of 2026 for prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, including data from 22 patients with at least 6 months of follow-up, 13 with at least 12 months. Adicet is advancing a potential pivotal trial design in lupus nephritis anticipated to start in the second half of 2026, subject to regulatory clearance. A regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer is expected in the third quarter of 2026, with Phase 1 enrollment anticipated in the fourth quarter of 2026, and an update on its in vivo CAR-T platform is planned for the second half of 2026. The company appointed board member Lloyd Klickstein, M.D., Ph.D., as Interim Chief Medical Officer.
Adicet Bio President & CEO Chen Schor received a new stock option award covering 55,000 shares of Common Stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
The grant vests over four years, with 1/48th of the options vesting on each of the next 48 monthly anniversaries of the grant date. A portion of the vesting can accelerate if specific performance milestones are met, as long as Schor maintains a service relationship with Adicet Bio on each vesting date.
Adicet Bio, Inc. reported that Chief Scientific Officer Blake Aftab received a grant of stock options covering 55,000 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.
These options were granted as compensation and are structured to vest over time. One forty-eighth of the options vests on each of the 48 monthly anniversaries of the grant date, with partial acceleration tied to certain performance milestones, as long as Aftab continues his service relationship with the company.
Adicet Bio director Steve Dubin received a new stock option grant covering 4,200 shares of common stock. The option has an exercise price of $8.10 per share and expires on June 20, 2036. It was awarded as compensation rather than through an open-market purchase or sale.
The option will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as Dubin continues serving on the board. Following this grant, he holds 4,200 option shares related to this award.
Adicet Bio director Jeffrey Chodakewitz received a new stock option award covering 4,200 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 20, 2036. Following this grant, he holds stock options for 4,200 underlying shares.
According to the terms, the options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant date, as long as he continues serving on Adicet Bio’s board of directors.
Adicet Bio director Michael Grissinger received a new stock option award covering 4,200 shares of Common Stock. The option was granted at an exercise price of $8.10 per share and expires on June 20, 2036. Following this grant, he holds options for 4,200 shares directly.
The award vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, as long as he continues serving on the board. This is a compensation-related grant, not an open‑market purchase or sale.
Adicet Bio, Inc. director Andrew Sinclair received a grant of stock options as part of his board compensation. He was awarded 4,200 stock options to purchase Adicet Bio common stock at an exercise price of $8.10 per share. These options expire on June 20, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders after the grant date, subject to his continued service on the board. Following this award, Sinclair holds 4,200 derivative securities linked to Adicet Bio common stock.